



MEDICAL TIPS

MEFTAL TABLETS

Issue II, No. 5, 2022

Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID-19: A randomized double-blind placebo-controlled trial

Guzman-Esquivel J et al. Int J of Molecular Medicine 2022; 49(29).

- Mefenamic acid is a NSAID exhibiting a wide range of anti-inflammatory, antipyretic, analgesic and probable anti-viral activities.
- 36 COVID-19 ambulatory patients were studied for the efficacy of treatment with mefenamic versus paracetamol in addition to the standard care in a parallel group, randomized, double-blind placebo-controlled trial.
- The time for each patient reaching a patient acceptable symptom state (PASS) along with the last day of COVID-19 symptom presentation was evaluated.
- Patients receiving mefenamic acid achieved PASS on day 4 as compared to 8 days with paracetamol. The lesser time and faster recovery was observed in Mefenamic group.

Due to its potent anti-inflammatory and probable antiviral effects, Mefenamic acid may prove to be useful in the treatment of COVID-19.

